<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.36485/1561-6274-2020-24-1-51-59</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-1790</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Скрининг инсулинорезистентности у больных на гемодиализе</article-title><trans-title-group xml:lang="en"><trans-title>Screening of insulin resistance in patients with hemodialysis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9455-1043</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Румянцев</surname><given-names>А. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Rumyantsev</surname><given-names>A. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Профессор Румянцев Александр Шаликович, доктор медицинских наук, кафедра факультетской терапии Санкт-Петербургского государственного университета;  кафедра пропедевтики внутренних болезней Первого Санкт-Петербургского государственного медицинского университета имени академика И.П. Павлова</p><p>199106, Санкт-Петербург, 21-я линия В.О., д. 8а197022, Санкт-Петербург, ул. Льва Толстого, д. 6–8</p></bio><bio xml:lang="en"><p>Prof. Rumyantsev Alexander Shalikovich, MD, PhD, DMedSci, St. Petersburg State University, department of faculty therapy;  Pavlov University, department of Propaedeutics of Internal Medicine</p></bio><email xlink:type="simple">rash.56@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8498-5454</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Филинюк</surname><given-names>П. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Filinyuk</surname><given-names>P. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Филинюк Павел Юрьевич, кафедра факультетской терапии</p><p>199106, Санкт-Петербург, 21-я линия В.О., д. 8а</p></bio><bio xml:lang="en"><p>Filinyuk Pavel Yuryevich, MD, department of faculty therapy</p></bio><email xlink:type="simple">pasha.filinyuk@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9455-1043</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коростелева</surname><given-names>Н. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Korosteleva</surname><given-names>N. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Коростелева Наталья Юрьевна, кандидат медицинских наук, НИИ нефрологии</p><p>197022, Санкт-Петербург, ул. Льва Толстого, д. 6–8</p></bio><bio xml:lang="en"><p>Natalya Yu. Korosteleva, MD, PhD, Research Institute of Nephrology, senior researcher</p></bio><email xlink:type="simple">natkor_spb@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0586-468X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Панина</surname><given-names>И. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Panina</surname><given-names>I. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Профессор Панина Ирина Юрьевна, доктор медицинских наук, кафедра пропедевтики внутренних болезней</p><p>197022, Санкт-Петербург, ул. Льва Толстого, д. 6–8</p></bio><bio xml:lang="en"><p>Prof. Irina Yu. Panina, MD, PhD, DMedSci, department of Propaedeutics of Internal Medicine</p><p>197022, L'va Tolstogo str. 6-8, Saint Petersburg</p></bio><email xlink:type="simple">i.u.panina@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Санкт-Петербургский государственный университет; &#13;
Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint-Petersburg State University; &#13;
Pavlov University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pavlov University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Санкт-Петербургский государственный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint-Petersburg State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>23</day><month>01</month><year>2020</year></pub-date><volume>24</volume><issue>1</issue><fpage>51</fpage><lpage>59</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Румянцев А.Ш., Филинюк П.Ю., Коростелева Н.Ю., Панина И.Ю., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Румянцев А.Ш., Филинюк П.Ю., Коростелева Н.Ю., Панина И.Ю.</copyright-holder><copyright-holder xml:lang="en">Rumyantsev A.S., Filinyuk P.Y., Korosteleva N.Y., Panina I.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/1790">https://journal.nephrolog.ru/jour/article/view/1790</self-uri><abstract><p>Резистентность к инсулину (ИР) определяют как нарушение биологического ответа на стимуляцию сердца, скелетных мышц, печени и жировой ткани. Причины формирования синдрома многообразны, а клиническая диагностика затруднена, так как нет общепринятого доступного теста для его определения. Для диагностики непосредственно ИР разработаны прямые и непрямые группы тестов. Сложность их выполнения в некоторых когортах пациентов привела к разработке ряда гликемических индексов. Однако пока не выработан консенсус относительно того, какой из них следует предпочесть. </p><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ: сравнить методы скрининга ИР в когорте пациентов на гемодиализе. </p></sec><sec><title>ПАЦИЕНТЫ И МЕТОДЫ</title><p>ПАЦИЕНТЫ И МЕТОДЫ. Обследованы 124 больных, из них 66 мужчин и 58 женщин в возрасте 57,6±13,6 года, получающих лечение ГД в течение 75,4±44,5 мес. Для скрининга ИР использовали модель гомеостаза глюкозы HOMA-1 и HOMA-2, индекс QUICKI и триглицериды/глюкоза (ТриГ).</p><p>При проведении непараметрического корреляционного анализа для концентрации в плазме инсулина натощак были выявлены статистически значимые взаимосвязи только у мужчин: с ИМТ (Rs=0,258; p=0,049), отношением окружности талии к росту (Rs=0,316; p=0,015), количеством пищевого белка (Rs=0,271; p=0,039), систолическим АД (Rs=0,308; p=0,018), диастолическим АД (Rs=0,290; p=0,027), уровнем С-реактивного белка (Rs=0,579; p=0,0001). У женщин статистически значимых корреляций не выявлено. Величина индекса Чарльсон, а также курение табака в настоящее время или в анамнезе на показатели инсулинорезистентности влияния не оказывали. По результатам логистического регрессионного анализа риск развития клинических проявлений атеросклеротического поражения любого сосудистого бассейна увеличивался в 4,5 раза (χ2=4,582; p=0,032) при ИР в модели HOMA-1 более 2,7 ед., однако, только у мужчин. Взаимосвязи других показателей ИР с атеросклерозом выявлено не было. </p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. Сравнение суррогатных моделей ИР, с нашей точки зрения, позволяет выделить HOMA-1 и HOMA-2. Вероятно, для поперечных исследований целесообразно использовать первую из них, а для продольных – вторую.</p></sec></abstract><trans-abstract xml:lang="en"><p>Insulin resistance (IR) is defined as a violation of the biological response to stimulation of the heart, skeletal muscle, liver, and adipose tissue. The reasons for the formation of the syndrome are diverse, and clinical diagnosis is difficult since there is no generally accepted test available to determine it. For the diagnosis of IR directly and indirectly developed test groups. The complexity of their implementation in some cohorts of patients led to the development of a number of glycemic indices. However, no consensus has yet been reached on which one should be preferred. </p><sec><title>THE AIM</title><p>THE AIM: to compare IR screening methods in a cohort of hemodialysis patients. </p></sec><sec><title>PATIENTS AND METHODS</title><p>PATIENTS AND METHODS. 124 patients were examined, including 66 men and 58 women aged 57.6 ± 13.6 years, receiving HD treatment for 75.4 ± 44.5 months. For the screening of IR, the HOMA-1 and HOMA-2 glucose homeostasis model, QUICKI index, and triglycerides/glucose (TriH) were used. </p></sec><sec><title>RESULTS</title><p>RESULTS. When conducting a nonparametric correlation analysis for fasting insulin plasma concentrations, statistically significant relationships were revealed only in men: with BMI (Rs = 0.258 p = 0.049), waist circumference to height ratio (Rs = 0.316 p = 0.015), and amount of dietary protein (Rs = 0.271 p = 0.039), systolic blood pressure (Rs = 0.308 p = 0.018), diastolic blood pressure (Rs = 0.290 p = 0.027), C-reactive protein level (Rs = 0.579 p = 0.0001). In women, no statistically significant correlations were found. The value of the Charlson index, as well as tobacco smoking, currently or in the history of the indicators of insulin resistance had no effect. According to the results of logistic regression analysis, the risk of developing clinical manifestations of atherosclerotic lesions of any vascular pool increased by 4.5 times (χ2 = 4.582 p = 0.032) with IR in the HOMA-1 model of more than 2.7 units, however, only in men. The relationship of other indicators of IR with atherosclerosis was not identified. </p></sec><sec><title>CONCLUSION</title><p>CONCLUSION. A comparison of surrogate models of IR, from our point of view, allows us to distinguish HOMA-1 and HOMA-2. Probably, for the cross-sectional studies it is advisable to use the first of them, and for longitudinal – the second.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>гемодиализ</kwd><kwd>инсулинорезистентность</kwd><kwd>модель HOMA-1</kwd><kwd>модель HOMA-2</kwd><kwd>QUICKI</kwd><kwd>triglycerides/glucose</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hemodialysis</kwd><kwd>insulin resistance</kwd><kwd>HOMA-1 and HOMA-2 glucose homeostasis model</kwd><kwd>QUICKI</kwd><kwd>triglycerides/glucose</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Zierath JR. Major Advances and Discoveries in Diabetes – 2019 in Review. Curr Diab Rep 2019;19(11):118. doi:10.1007/s11892-019-1255-x</mixed-citation><mixed-citation xml:lang="en">Zierath JR. Major Advances and Discoveries in Diabetes – 2019 in Review. Curr Diab Rep 2019;19(11):118. doi:10.1007/s11892-019-1255-x</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Hossan T, Kundu S, Alam SS, Nagarajan S. Epigenetic Modifications Associated with the Pathogenesis of Type 2 Diabetes Mellitus. Endocr Metab Immune Disord Drug Targets 2019;19(6):775–778. doi: 10.2174/1871530319666190301145545</mixed-citation><mixed-citation xml:lang="en">Hossan T, Kundu S, Alam SS, Nagarajan S. Epigenetic Modifications Associated with the Pathogenesis of Type 2 Diabetes Mellitus. Endocr Metab Immune Disord Drug Targets 2019;19(6):775–778. doi: 10.2174/1871530319666190301145545</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Himsworth HP, Kerr RB. Insulin-sensitive and Insulininsensitive types diabetes mellitus. Clin Sci 1939;(4):119–152</mixed-citation><mixed-citation xml:lang="en">Himsworth HP, Kerr RB. Insulin-sensitive and Insulininsensitive types diabetes mellitus. Clin Sci 1939;(4):119–152</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Calvano A, Izuora K, Oh EC, Ebersole JL et al. Dietary berries, insulin resistance and type 2 diabetes: an overview of human feeding trials. Food Funct 2019 Oct 16;10(10):6227–6243. doi: 10.1039/c9fo01426h</mixed-citation><mixed-citation xml:lang="en">Calvano A, Izuora K, Oh EC, Ebersole JL et al. Dietary berries, insulin resistance and type 2 diabetes: an overview of human feeding trials. Food Funct 2019 Oct 16;10(10):6227–6243. doi: 10.1039/c9fo01426h</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Govers E, Slof E, Verkoelen H, Ten Hoor-Aukema NM, KDOO (2015) Guideline for the Management of Insulin Resistance. Int J Endocrinol Metab Disord 2015;1(4): 1–10. doi: 10.16966/2380548X.115</mixed-citation><mixed-citation xml:lang="en">Govers E, Slof E, Verkoelen H, Ten Hoor-Aukema NM, KDOO (2015) Guideline for the Management of Insulin Resistance. Int J Endocrinol Metab Disord 2015;1(4): 1–10.  doi: 10.16966/2380548X.115</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Borai A, Livingstone C, Kaddam I, Ferns G. Selection of the appropriate method for the assessment of insulin resistance. BMC Med Res Methodol 2011;11:158. doi:10.1186/1471-2288-11-158</mixed-citation><mixed-citation xml:lang="en">Borai A, Livingstone C, Kaddam I, Ferns G. Selection of the appropriate method for the assessment of insulin resistance. BMC Med Res Methodol 2011;11:158. doi:10.1186/1471-2288-11-158</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Творогова МГ, Яськова КН, Мычка ВБ, Чазова ИЕ. Инсулинорезистентность и методы ее диагностики. Лабораторная медицина 2003; (6):48–52</mixed-citation><mixed-citation xml:lang="en">Tvorogova MG, Yaskova KN, Mychka VB, Chazova I.E. Insulin resistance and methods for its diagnosis. Laboratory Medicine 2003; (6): 48–52</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419</mixed-citation><mixed-citation xml:lang="en">Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wallace TM, Levy JC, Matthews DR Use and abuse of HOMA modeling. Diabetes Care 2004; 27:1487–1495</mixed-citation><mixed-citation xml:lang="en">Wallace TM, Levy JC, Matthews DR Use and abuse of HOMA modeling. Diabetes Care 2004; 27:1487–1495</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Salazar J, Bermudez, Calvo M et al. Optimal cutoff for the evaluation of insulin resistance through triglyceride-glucose index: A cross-sectional study in a Venezuelan population. Version 3. F1000Res. 2017; 6: 1337</mixed-citation><mixed-citation xml:lang="en">Salazar J, Bermudez, Calvo M et al. Optimal cutoff for the evaluation of insulin resistance through triglyceride-glucose index: A cross-sectional study in a Venezuelan population. Version 3. F1000Res. 2017; 6: 1337</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">http://www.dtu.ox.ac.uk/homacalculator/index.php</mixed-citation><mixed-citation xml:lang="en">http://www.dtu.ox.ac.uk/homacalculator/index.php</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Singh B, Saxena A. Surrogate markers of insulin resistance: A review. World J Diabetes 2010; 1(2): 36–47. doi:10.4239/wjd.v1.i2.36</mixed-citation><mixed-citation xml:lang="en">Singh B, Saxena A. Surrogate markers of insulin resistance: A review. World J Diabetes 2010; 1(2): 36–47. doi:10.4239/wjd.v1.i2.36</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Sujit Bhattacharya S. Carbohydrate Metabolism in Chronic Kidney Disease. JOJ Uro&amp;Nephron 2018; 5(3): 555662. doi:10.19080/JOJUN.2018.05.555662</mixed-citation><mixed-citation xml:lang="en">Sujit Bhattacharya S. Carbohydrate Metabolism in Chronic Kidney Disease. JOJ Uro&amp;Nephron 2018; 5(3): 555662. doi:10.19080/JOJUN.2018.05.555662</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Rahhal MN, Gharaibeh NE, Rahimi L, Ismail-Beigi F. Disturbances in Insulin-Glucose Metabolism in Patients With Advanced Renal Disease With and Without Diabetes. J Clin Endocrinol Metab 2019 Nov 1;104(11):4949–4966. doi: 10.1210/jc.2019-00286</mixed-citation><mixed-citation xml:lang="en">Rahhal MN, Gharaibeh NE, Rahimi L, Ismail-Beigi F. Disturbances in Insulin-Glucose Metabolism in Patients With Advanced Renal Disease With and Without Diabetes. J Clin Endocrinol Metab 2019 Nov 1;104(11):4949–4966. doi: 10.1210/jc.2019-00286</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kraegen EW, Saha AK, Preston E et al. Increased malonylCoA and diacylglycerol content and reduced AMPK activity accompany insulin resistance induced by glucose infusion in muscle and liver of rats. Am J Physiol Endocrinol Metab 2006;290:E471–E479</mixed-citation><mixed-citation xml:lang="en">Kraegen EW, Saha AK, Preston E et al. Increased malonylCoA and diacylglycerol content and reduced AMPK activity accompany insulin resistance induced by glucose infusion in muscle and liver of rats. Am J Physiol Endocrinol Metab 2006;290:E471–E479</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008;118:2992–3002</mixed-citation><mixed-citation xml:lang="en">Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008;118:2992–3002</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hoehn KL, Salmon AB, Hohnen-Behrens C et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc Natl Acad Sci USA 2009;106:17787–17792</mixed-citation><mixed-citation xml:lang="en">Hoehn KL, Salmon AB, Hohnen-Behrens C et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc Natl Acad Sci USA 2009;106:17787–17792</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Nolan CJ, Ruderman NB, Prentki M. Intensive insulin for type 2 diabetes: the risk of causing harm. Lancet Diabetes Endocrinol 2013;1:9–10</mixed-citation><mixed-citation xml:lang="en">Nolan CJ, Ruderman NB, Prentki M. Intensive insulin for type 2 diabetes: the risk of causing harm. Lancet Diabetes Endocrinol 2013;1:9–10</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003;14:398–403</mixed-citation><mixed-citation xml:lang="en">Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003;14:398–403</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785–789</mixed-citation><mixed-citation xml:lang="en">Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785–789</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093–1129</mixed-citation><mixed-citation xml:lang="en">Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093–1129</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Chess DJ, Stanley WC. Role of diet and fuel overabundance in the development and progression of heart failure. Cardiovasc Res 2008;79:269–278</mixed-citation><mixed-citation xml:lang="en">Chess DJ, Stanley WC. Role of diet and fuel overabundance in the development and progression of heart failure. Cardiovasc Res 2008;79:269–278</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Labbe SM, Grenier-Larouche T, Noll C et al. Increased myocardial uptake of dietary fatty acids linked to cardiac dysfunction in glucose-intolerant humans. Diabetes 2012;61:2701–2710</mixed-citation><mixed-citation xml:lang="en">Labbe SM, Grenier-Larouche T, Noll C et al. Increased myocardial uptake of dietary fatty acids linked to cardiac dysfunction in glucose-intolerant humans. Diabetes 2012;61:2701–2710</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Prentki M, Corkey BE, Madiraju SRM. Lipid-associated metabolic signalling networks in pancreatic beta cell function. Diabetologia 2020 Jan;63(1):10–20. doi: 10.1007/s00125-019-04976-w</mixed-citation><mixed-citation xml:lang="en">Prentki M, Corkey BE, Madiraju SRM. Lipid-associated metabolic signalling networks in pancreatic beta cell function. Diabetologia 2020 Jan;63(1):10–20. doi: 10.1007/s00125-019-04976-w</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Wright JJ, Kim J, Buchanan J. Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc Res 2009 May 1;82(2):351–360. doi: 10.1093/cvr/cvp017</mixed-citation><mixed-citation xml:lang="en">Wright JJ, Kim J, Buchanan J. Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc Res 2009 May 1;82(2):351–360. doi: 10.1093/cvr/cvp017</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Smith U. Abdominal obesity: a marker of ectopic fat accumulation. J Clin Invest 2015;125(5):1790–1792. doi:10.1172/JCI81507</mixed-citation><mixed-citation xml:lang="en">Smith U. Abdominal obesity: a marker of ectopic fat accumulation. J Clin Invest 2015;125(5):1790–1792. doi:10.1172/JCI81507</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. Obes Rev 2014 Jun;15(6):504–515. doi: 10.1111/obr.12157</mixed-citation><mixed-citation xml:lang="en">Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. Obes Rev 2014 Jun;15(6):504–515. doi: 10.1111/obr.12157</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Huxley R, Mendis S, Zheleznyakov E, Reddy S, Chan J. Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk-a review of the literature. Eur J Clin Nutr 2010 Jan;64(1):16–22. doi: 10.1038/ejcn.2009.68</mixed-citation><mixed-citation xml:lang="en">Huxley R, Mendis S, Zheleznyakov E, Reddy S, Chan J. Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk-a review of the literature. Eur J Clin Nutr 2010 Jan;64(1):16–22. doi: 10.1038/ejcn.2009.68</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou W, Shi Y, Li YQ et al. Body mass index, abdominal fatness, and hypertension incidence: a dose-response meta-analysis of prospective studies. J Hum Hypertens 2018 May;32(5):321– 333. doi: 10.1038/s41371-018-0046-1</mixed-citation><mixed-citation xml:lang="en">Zhou W, Shi Y, Li YQ et al. Body mass index, abdominal fatness, and hypertension incidence: a dose-response meta-analysis of prospective studies. J Hum Hypertens 2018 May;32(5):321– 333. doi: 10.1038/s41371-018-0046-1</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Selthofer-Relatic K, Radic R, Stupin A, Sisljagic V et al. Leptin/adiponectin ratio in overweight patients – gender differences. Diab Vasc Dis Res 2018 May;15(3):260–262. doi: 10.1177/1479164117752491</mixed-citation><mixed-citation xml:lang="en">Selthofer-Relatic K, Radic R, Stupin A, Sisljagic V et al. Leptin/adiponectin ratio in overweight patients – gender differences. Diab Vasc Dis Res 2018 May;15(3):260–262. doi: 10.1177/1479164117752491</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Hecking M, Bieber BA, Ethier J et al. Sex-Specific Differences in Hemodialysis Prevalence and Practices and the Maleto-Female Mortality Rate: The Dialysis Outcomes and Practice Patterns Study (DOPPS). PLoS Med 2014 Oct; 11(10): e1001750. doi: 10.1371/journal.pmed.1001750</mixed-citation><mixed-citation xml:lang="en">Hecking M, Bieber BA, Ethier J et al. Sex-Specific Differences in Hemodialysis Prevalence and Practices and the Maleto-Female Mortality Rate: The Dialysis Outcomes and Practice Patterns Study (DOPPS). PLoS Med 2014 Oct; 11(10): e1001750. doi: 10.1371/journal.pmed.1001750</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Burmeister JE, Mosmann CB, Costa VB et al. Prevalence of cardiovascular risk factors in hemodialysis patients – The CORDIAL study. Arq Bras Cardiol 2014;102(5):473–480. doi:10.5935/abc.20140048</mixed-citation><mixed-citation xml:lang="en">Burmeister JE, Mosmann CB, Costa VB et al. Prevalence of cardiovascular risk factors in hemodialysis patients – The CORDIAL study. Arq Bras Cardiol 2014;102(5):473–480. doi:10.5935/abc.20140048</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Drawz PE, Baraniuk S, Davis BR et al. Cardiovascular risk assessment: addition of CKD and race to the Framingham equation. Am Heart J 2012;164(6):925–931.e2. doi:10.1016/j.ahj.2012.09.003]</mixed-citation><mixed-citation xml:lang="en">Drawz PE, Baraniuk S, Davis BR et al. Cardiovascular risk assessment: addition of CKD and race to the Framingham equation. Am Heart J 2012;164(6):925–931.e2. doi:10.1016/j.ahj.2012.09.003]</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
